Novo Nordisk A S (NONOF) stock
NONOFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVO
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$38.24−0.60 (-1.53%)
Close on Oct 19, 2026Market cap $170.76BP/E 11.1Yield –
Novo Nordisk A S r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was 52.04B DKK, up 8.3% from the year before. Over ten years it grew 14.4% a year on average. The highest annual figure on record is 52.04B DKK in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.04B DKK | +8.3% |
| FY2024 | Dec 31, 2024 | 48.06B DKK | +48.1% |
| FY2023 | Dec 31, 2023 | 32.44B DKK | +34.9% |
| FY2022 | Dec 31, 2022 | 24.05B DKK | +35.3% |
| FY2021 | Dec 31, 2021 | 17.77B DKK | +14.9% |
| FY2020 | Dec 31, 2020 | 15.46B DKK | +8.7% |
| FY2019 | Dec 31, 2019 | 14.22B DKK | -4.0% |
| FY2018 | Dec 31, 2018 | 14.81B DKK | +5.6% |
| FY2017 | Dec 31, 2017 | 14.01B DKK | -3.8% |
| FY2016 | Dec 31, 2016 | 14.56B DKK | +7.0% |
| FY2015 | Dec 31, 2015 | 13.61B DKK | – |
See a number that looks wrong?